Digest Réseau Comment ça marche
Réseau
/
Sociétés
No
Non vérifié

Novo Nordisk A/S

Ce que nous écrivons

FinanceIndustrie pharmaceutiqueManagement/Organisation d'EntreprisePolitique ÉtrangèrePublicité/Marketing/Médias/Communication

82 communiqués de presse

Voir tous les communiqués de presse
19/03/2026
Industrie pharmaceutique
Politique Étrangère
Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
02/03/2026
Industrie pharmaceutique
Politique Étrangère
Election of employee representatives to the Board of Directors of Novo Nordisk A/S
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
02/03/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Novo Nordisk announces more than 400 million euro expansion in its manufacturing facility in Athlone, Ireland
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
25/02/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Management/Organisation d'Entreprise
Novo Nordisk and Vivtex partner to develop next-generation oral medicines for obesity and diabetes
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
24/02/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Novo Nordisk: Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
23/02/2026
Industrie pharmaceutique
Politique Étrangère
Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
20/02/2026
Industrie pharmaceutique
Politique Étrangère
Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
17/02/2026
Industrie pharmaceutique
Médecine Santé Bien-être
Novo Nordisk A/S: The European Commission approves more effective dose of injectable Wegovy® for adults with obesity; clinical study showed people lost about 21% of their body weight on average
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
05/02/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Novo Nordisk issues statement on illegal mass compounding and deceptive advertising by Hims & Hers
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
04/02/2026
Industrie pharmaceutique
Finance
Novo Nordisk files annual report with the SEC
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0